度伐利尤单抗继发的视网膜血管炎
Retinal Vasculitis Secondary to Durvalumab.
作者信息
R Andrade Antonio, Moll-Udina Aina, Martin Ruth, Cilveti Esther, Subirà Olaia, Disfetano Laura, García-Arumí Jose
机构信息
Ophthalmology Department, Vall d'Hebron, Facultat de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
Ophthalmology Department, Hospital Clínic de Barcelona, Instituto Clínic de Oftalmología, Barcelona, Spain.
出版信息
Case Rep Ophthalmol. 2020 May 5;11(2):161-166. doi: 10.1159/000507609. eCollection 2020 May-Aug.
Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We present a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of methylprednisolone, the retinal vasculitis resolved and macular edema improved during follow-up. There was no need for durvalumab to be withdrawn.
眼部表现作为检查点抑制剂的副作用很少被报道。我们报告一例64岁的白种男性，他正在接受度伐利尤单抗治疗非小细胞肺癌，出现了伴有黄斑水肿的视网膜血管炎。在静脉注射三次甲泼尼龙后，视网膜血管炎消退，随访期间黄斑水肿有所改善。无需停用度伐利尤单抗。
Zotero 插件